In Vitro Activity of Plazomicin against Gram-negative and Gram-positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017: CANWARD Surveillance Study [Susceptibility]

The Clinical and Laboratory Standards Institute (CLSI) broth microdilution method was used to evaluate the in vitro activities of plazomicin and comparator antimicrobial agents against 7,712 Gram-negative and 4,481 Gram-positive bacterial pathogens obtained from patients in Canadian hospitals (CANWARD, 2013 to 2017). Plazomicin demonstrated potent in vitro activity against Enterobacteriaceae (MIC₉₀ ≤1 µg/ml for all species tested except Proteus mirabilis and Morganella morganii), including aminoglycoside non-susceptible, extended-spectrum β-lactamase (ESBL)-positive, and multidrug-resistant (MDR) isolates. Plazomicin was equally active against methicillin-susceptible and methicillin-resistant isolates of Staphylococcus aureus.

https://ift.tt/2CQtzPO